We studied the PROTACs that can bind to both BRD4 and E3 ligase protein. The present study investigated how PROTACs inhibit the BRD4 protein and can aid in treatment of neuroblastoma. The present study was grounded on the recent discoveries of Jia et al., who found that BRD4 protein inhibitors manifest anti-neuroblastoma activity. Their research utilizing mice showed that the BRD4 protein suppression by PROTAC was dose-dependent, leading to apoptosis and cell-cycle arrest . In order to investigate protein-PROTAC interactions, our research employed in silico methodologies like molecular docking simulations. In addition, we also generated the PROTAC library by performing mutations in PROTAC. Ultimately, the most effective PROTAC has been identified based on the PROTAC interactions formed with both proteins. The current work comprises 10 PROTACs and for the sake of simplicity they are designated as PROTAC I, II, III, IV, V, VI, VII, VIII, IX, and X.